Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 146

Showing 51-75 of 146 citing articles:

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
Application of PROTACs in target identification and validation
Yang Liu, Jing Liang, Rui Zhu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 5
MOF-based nanoparticles for tumor-targeted protein degradation and photodynamic therapy induce enhanced anti-tumor immunity
Huanhuan Zhu, Fei Gao, Yuan Li, et al.
Nano Today (2024) Vol. 56, pp. 102308-102308
Closed Access | Times Cited: 5
Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment
Lianlian Fan, Weifang Tong, Anhui Wei, et al.
International Journal of Biological Macromolecules (2024) Vol. 275, pp. 133680-133680
Open Access | Times Cited: 5
Targeted degradation of LRG1 to attenuate renal fibrosis
Linyao Fan, Yingqiu Qi, Xi Yang, et al.
Asian Journal of Pharmaceutical Sciences (2024) Vol. 19, Iss. 4, pp. 100941-100941
Open Access | Times Cited: 5
Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy
Xinchen Lu, Jinmei Jin, Ye Wu, et al.
Bioactive Materials (2024) Vol. 43, pp. 255-272
Open Access | Times Cited: 5
ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy
Xucong Teng, Xuan Zhao, Yicong Dai, et al.
Journal of the American Chemical Society (2024)
Closed Access | Times Cited: 5
Staudinger Reaction-Responsive Coacervates for Cytosolic Antibody Delivery and TRIM21-Mediated Protein Degradation
Yishu Bao, Zhiyi Xu, Kai Cheng, et al.
Journal of the American Chemical Society (2025)
Closed Access
Research Progress in DNA Damage Response (DDR)-Targeting Modulators: from Hits to Clinical Candidates
Binbin Cheng, Zongbao Ding, Yun Hong, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117347-117347
Closed Access
USP13: A therapeutic target for combating tumorigenesis and antitumor therapy resistance
Lina Yi, Akezhouli Shahatiaili, Lin Zhang, et al.
International Journal of Biological Macromolecules (2025), pp. 140608-140608
Closed Access
Workflow for E3 Ligase Ligand Validation for PROTAC Development
Nebojša Miletić, Janik Weckesser, Thorsten Mosler, et al.
ACS Chemical Biology (2025)
Open Access
A Dual-Targeted Molecule for Disease-Activatable Proteolysis Targeting Chimeras and Targeted Radionuclide Therapy of Cancer
Yuan Zhang, Wei Gu, Chen Wan, et al.
Journal of the American Chemical Society (2025) Vol. 147, Iss. 9, pp. 7897-7907
Closed Access
Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects
Qin Ru, Yusheng Li, Feng Zhang, et al.
Bone Research (2025) Vol. 13, Iss. 1
Open Access
A Comprehensive Primer and Review of PROTACs and Their In Silico Design
Jacopo Zattoni, Paola Vottero, Gea Carena, et al.
Computer Methods and Programs in Biomedicine (2025) Vol. 264, pp. 108687-108687
Open Access
Self‐Oxygenating PROTAC Microneedle for Spatiotemporally‐Confined Protein Degradation and Enhanced Glioblastoma Therapy
Xingyu Jiang, Yi Lai, Wenzheng Xia, et al.
Advanced Materials (2025)
Open Access
Dual-Action-Only PROTACs
Ranit Dutta, Anirudh Devarajan, Amelia Talluri, et al.
Journal of the American Chemical Society (2025)
Closed Access
MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell
Zheng Yuan, Meixia Guo, Yue Zhang, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Current strategies for senescence treatment: Focused on theranostic performance of nanomaterials
Yiyang Cong, Xiaoyang Li, Hao Hong
Journal of Controlled Release (2025), pp. 113710-113710
Closed Access
Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives
Jiao Li, Zhenyu Cai, Xu‐Wen Li, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 13533-13560
Closed Access | Times Cited: 20
Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells
Yuying Shi, An-Jin Wang, Xuelian Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Central Nervous System Targeted Protein Degraders
Bedwyr ab Ion Thomas, H Lewis, D. Heulyn Jones, et al.
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1164-1164
Open Access | Times Cited: 11
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review
Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 7, pp. 529-545
Closed Access | Times Cited: 4
Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders
Sarah F. Giardina, Elena Valdambrini, Pradeep K. Singh, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5473-5501
Closed Access | Times Cited: 4
Autophagy mediated targeting degradation, a promising strategy in drug development
Jiantao Zhang, Xiangyi Pan, Wenshu Ji, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107466-107466
Closed Access | Times Cited: 4
Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Yue Song, Qing‐Qing Dong, Yi-Ke Ni, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 5739-5761
Open Access | Times Cited: 4

Scroll to top